GHdC

Charleroi 6000

0 studies enrolling now · 1 studies all time

What they study most

HER2-positive Breast Cancer

Studies at this site

• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling